Journal
ENDOCRINE-RELATED CANCER
Volume 18, Issue 3, Pages R79-R89Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-10-0162
Keywords
-
Categories
Ask authors/readers for more resources
The introduction of aromatase inhibitors (AI) has provided more options for adjuvant treatment of postmenopausal women; they are associated with improved disease-free survival, but less commonly with improvements in overall survival. Current evidence suggests that women at high risk of recurrence, especially those with node-positive disease, should receive an AI for 2 years as part of their treatment, but routine prescription of AIs to postmenopausal patients with low-risk disease is not appropriate. Not only the expected benefits but also the specific toxicity of the prescribed hormone therapy, and its cost, should be considered when selecting treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available